Featured Research

from universities, journals, and other organizations

Common Reflux Treatment Linked To Life Threatening Bowel Infection In Premature Infants

Date:
February 9, 2006
Source:
NIH/National Institute of Child Health and Human Development
Summary:
Researchers in a National Institutes of Health network have found that premature infants given a common class of non-prescription drugs used to treat acid reflux are slightly more likely to develop a potentially fatal bowel disorder than are infants who are not treated with the drugs.

Researchers in an NIH network have found that premature infants given a common class of non-prescription drugs used to treat acid reflux are slightly more likely to develop a potentially fatal bowel disorder than are infants who are not treated with the drugs.

The drugs, known as H2 blockers, inhibit the production of stomach acid and may put premature infants at risk of necrotizing enterocolitis, a serious inflammation of the intestines. The study appears in the February 2006 Pediatrics and was conducted by researchers in the NIH's National Institute of Child Health and Human Development Neonatal Research Network.

The researchers pointed out that it is not possible to tell from the study whether or not the drugs caused the condition, but nonetheless advised caution with their use for premature infants.

"This study strongly suggests that the current practice of prescribing H2 blockers to prevent or treat acid reflux in premature infants needs to be carefully reevaluated by all concerned in light of these new findings," said Elias A. Zerhouni, M.D., Director of the National Institutes of Health.

Necrotizing enterocolitis affects from 5 to 10 percent of infants born extremely prematurely, explained the study's first author, Ronnie Guillet, M.D., Ph.D., of the University of Rochester in Rochester, New York, a member institution of the NICHD Neonatal Research Network.

With necrotizing enterocolitis, tissue lining the wall of the intestines dies. The surviving tissue becomes swollen and inflamed, and the digestive tract is unable to digest or transport food. In some cases, damage to the intestines may require that portions of the intestines be removed. In other cases, the damage is so severe that the infant dies. The cause of the disorder is unknown.

Common H2 blockers are cimetidine (Tagamet), famotidine (Pepcid), ranitidine (Zantac), and nizatidine (Axid).

To conduct the study, Dr. Guillet and her coworkers analyzed the records of more than 11,000 very low birth weight infants who had been treated in the NICHD Neonatal Research Network. Of these, 787 premature infants had developed necrotizing enterocolitis. The infants ranged in weight from 401 grams to 1500 grams (about 14 ounces to just over 3 lbs). The researchers found that infants who received H2 blockers were 1.71 times more likely to develop necrotizing enterocolitis than were infants who had not received them.

In their article, Dr. Guillet and her coauthors wrote that it is not possible to determine from the analysis whether or not H2 blockers cause necrotizing enterocolitis. Another possible explanation, they wrote, is that infants likely to develop necrotizing enterocolitis might also have symptoms that require treatment with H2 blockers. The records that the researchers analyzed did not contain information on why physicians prescribed the drugs.

No other studies have been conducted on large numbers of premature infants receiving H2 blockers, said the program scientist of the NICHD Neonatal Research Network, Rosemary Higgins, M.D., of NICHD's Pregnancy and Perinatology Branch. However, the practice is widespread in neonatal intensive care units around the country.

Physicians prescribe H2 blockers to premature infants for several reasons, Dr. Higgins said. If premature infants are experiencing a lot of acid reflux, physicians might prescribe the drugs to prevent damage to the esophagus.

Dr. Higgins added that some physicians may prescribe H2 blockers to a premature infant who is not experiencing reflux out of concern that excessive stomach acid may lead to stomach ulcers. Some physicians believe that reflux may predispose an infant to apnea—the cessation of breathing during sleep. Dr. Higgins said that this belief is controversial and no research has been conducted to determine its validity. In other cases, physicians may prescribe H2 blockers to prevent excess stomach acidity among infants who, because they are unable to feed unassisted, must be fed through a tube inserted through the esophagus.

In the paper, Dr. Guillet and her coworkers hypothesized that, by decreasing acidity in the digestive tract, H2 blockers might result in excessive levels of a type of bacteria known as gram negative bacteria. These high bacterial levels, in turn, might lead to necrotizing entercolitis. The gram negative bacteria, normally harmless, are presumably kept in check by stomach acid, and might increase to unhealthy levels in the absence of sufficient stomach acid.

In support of their hypothesis, the researchers cited a study which found that experimental animals with reduced stomach acid levels had higher levels of gram negative bacteria and a high likelihood of developing necrotizing enterocolitis. The researchers also cited a study which found that premature infants fed human milk with a slightly higher acidity level than normal had lower levels of gram negative bacteria and were less likely to develop necrotizing enterocolitis than were infants fed milk with a normal acidity level.

The researchers did not study any other drugs used to reduce stomach acidity and do not know whether premature infants given these drugs have an increased likelihood of necrotizing enterocolitis.

###

The NICHD is part of the National Institutes of Health (NIH), the biomedical research arm of the federal government. NIH is an agency of the U.S. Department of Health and Human Services. The NICHD sponsors research on development, before and after birth; maternal, child, and family health; reproductive biology and population issues; and medical rehabilitation.


Story Source:

The above story is based on materials provided by NIH/National Institute of Child Health and Human Development. Note: Materials may be edited for content and length.


Cite This Page:

NIH/National Institute of Child Health and Human Development. "Common Reflux Treatment Linked To Life Threatening Bowel Infection In Premature Infants." ScienceDaily. ScienceDaily, 9 February 2006. <www.sciencedaily.com/releases/2006/02/060209084046.htm>.
NIH/National Institute of Child Health and Human Development. (2006, February 9). Common Reflux Treatment Linked To Life Threatening Bowel Infection In Premature Infants. ScienceDaily. Retrieved September 3, 2014 from www.sciencedaily.com/releases/2006/02/060209084046.htm
NIH/National Institute of Child Health and Human Development. "Common Reflux Treatment Linked To Life Threatening Bowel Infection In Premature Infants." ScienceDaily. www.sciencedaily.com/releases/2006/02/060209084046.htm (accessed September 3, 2014).

Share This



More Health & Medicine News

Wednesday, September 3, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Snack Attack: Study Says Action Movies Make You Snack More

Snack Attack: Study Says Action Movies Make You Snack More

Newsy (Sep. 2, 2014) You're more likely to gain weight while watching action flicks than you are watching other types of programming, says a new study published in JAMA. Video provided by Newsy
Powered by NewsLook.com
U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

Newsy (Sep. 2, 2014) The U.N. says the problem is two-fold — quarantine zones and travel restrictions are limiting the movement of both people and food. Video provided by Newsy
Powered by NewsLook.com
Doctors Fear They're Losing Battle Against Ebola

Doctors Fear They're Losing Battle Against Ebola

AP (Sep. 2, 2014) As a third American missionary is confirmed to have contracted Ebola in Liberia, doctors on the ground in West Africa fear they're losing the battle against the outbreak. (Sept. 2) Video provided by AP
Powered by NewsLook.com
Tech Giants Bet on 3D Headsets for Gaming, Healthcare

Tech Giants Bet on 3D Headsets for Gaming, Healthcare

AFP (Sep. 2, 2014) When Facebook acquired the virtual reality hardware developer Oculus VR in March for $2 billion, CEO Mark Zuckerberg hailed the firm's technology as "a new communication platform." Duration: 02:24 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins